Signal of safety due to adverse drug reactions induced by tacrolimus with or without azithromycin

Ryo Yonezawa,Tomiko Sunaga

DOI: https://doi.org/10.1111/tid.13833

2022-04-20

Transplant Infectious Disease

Abstract:IntroductionWe identified two reports of drug levels increased and acute kidney injury caused by the drug–drug interaction between azithromycin (AZM) and tacrolimus (TAC). However, it is unclear whether the combined of these two drugs causes additive or synergistic adverse drug reactions. Therefore, we evaluated the disproportionality in reporting drug level increased and acute kidney injury for these two drugs are used alone and in combination with each other.MethodData from the U.S. Food and Drug Administration's Adverse Event Reporting System from 1974 to Q3/2021 were used. Reports based on exposure to macrolide antibiotic alone, TAC alone, and each macrolide antibiotic + TAC were extracted. Proportional Reporting Ratios (PRR) and 95% confidence intervals (CI) were calculated, and a lower limit of the 95% CI (Lower95CI) value of 2.0 or higher was interpreted as a signal of safety.ResultsLower95CIs for macrolide antibiotic alone and TAC showed no potential signals of safety, including drug level increased, acute kidney injury, and control event. The PRRs and 95% CI for drug level increased was 3.27 (2.69–3.97) with AZM + TAC, and 10.81 (9.59–12.17) for clarithromycin (CAM) + TAC. For CAM + TAC, the PRR and 95% CI was 8.42 (7.51–9.44) in acute kidney injury. However, AZM + TAC was not associated with a signal of safety in acute kidney injury.ConclusionsThis suggests that AZM + TAC has a low risk of causing acute kidney injury but may cause drug level increased.This article is protected by copyright. All rights reserved

immunology,infectious diseases,transplantation